Recent studies have shown that STF-083010, an inhibitor for XBP1, can restore sensitivity to tamoxifen in tamoxifen resistant MCF-7 cell lines and a synergistic effect of both drugs significantly delay breast cancer progression. Here, XBP1 is linked to breast cancer.